TGFB1 and fungal infectious disease: However, given that LAP is known to be involved in anti-inflammatory pathways such as the efferocytosis of apoptotic bodies and the anti-microbial clearance of bacterial and fungal infections, systematically targeting the LAP PI3KC3 complex could have undesirable side effects that result in chronic inflammation and prolonged infections.